A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma
Latest Information Update: 23 Mar 2022
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 25 Feb 2022 Status changed from suspended to discontinued.
- 20 Oct 2021 Planned End Date changed from 1 Dec 2024 to 19 Dec 2021.
- 20 Oct 2021 Status changed from recruiting to suspended.